Safety and Feasibility Study of the Shockwave Lithoplasty System

Vascular Disease Clinical Trial

Official title:

Safety and Feasibility Study of the Shockwave Lithoplasty System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01577888
• Other study ID #: TD-0047
• Status: Completed
• Phase: N/A
• First received: April 11, 2012
• Last updated: August 6, 2014
• Start date: August 2012
• Est. completion date: August 2014

Study information

• Verified date: August 2014
• Source: Shockwave Medical, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: New Zealand: Health and Disability Ethics Committees
• Study type: Interventional

Clinical Trial Summary

To study the early safety and performance of the Shockwave Medical System in subjects to demonstrate that the device can safely and effectively deliver localized energy for the treatment of vascular disease.

Description:

Shockwave Medical, Inc. intends to conduct a prospective, single-arm, single-center, First in Human study designed to evaluate the early safety and feasibility of the Shockwave Lithoplasty System in subjects with heavily calcified infrainguinal arteries with 3.75mm to 6mm reference vessel diameter at target site. The Shockwave Lithoplasty System is indicated to generate sonic shockwave energy within the target treatment site and disrupt calcium within the lesion to allow for subsequent dilation of a peripheral artery stenosis using low balloon pressure. Up to 10 subjects will be enrolled to undergo lihtoplasty.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18

• Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form.

• Female subjects of childbearing potential have a negative pregnancy test less than 7 days before the procedure.

• Patient is able and willing to comply with all assessments in the study.

• Peripheral arterial disease of Rutherford Category 2, 3, 4, and 5.

• Ability to tolerate an antiplatelet agent (i.e. aspirin, clopidigrel or prasagrel).

• Meets Angiographic Inclusion Criteria

Exclusion Criteria:

• Patients with peripheral arterial disease of Rutherford Category 6.

• Severe or infected gangrene of the lower extremity.

• Planned major amputation.

• Previously implanted stent at the treatment site.

• Patient with an externally-connected intracardiac catheter or pacemaker.

• Patient with an implantable pacemaker or defibrillator.

• Patient has connective tissue disease (e.g., Marfan's syndrome).

• Patient has a hypercoagulable disorder.

• Patient has allergy to imaging contrast media for which they cannot be premedicated.

• Patient is in acute renal failure or chronic renal insufficiency or failure as measured by a serum creatinine of >19.5 µmol/L.

• Patient has active systemic infection.

• Patient has less than a one year life expectancy.

• Patient is pregnant or nursing.

• Patient is participating in another research study involving an investigational agent that has not reached the primary endpoint.

• Patient has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.

• Chronic total occlusion of target vessel.

• Chronic total occlusion of inflow vessel.

• Highly tortuous arteries (bends greater than 30 degrees over the arc length of the balloon)

• Patients requiring concurrent intervention below the most distal target lesion.

• Inflow disease: Stenosis of >50% in vessel proximal to the target lesion which requires treatment with Drug Eluting Balloon (DEB) or atherectomy.

• Prior procedure in target leg within past 3 months.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Vascular Disease
• Vascular Diseases

Intervention

Device:
• Shockwave System Treatment
Shockwave System Treatment during vascular disease intervention.

Locations

Country	Name	City	State
New Zealand	Auckland City Hospital	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Shockwave Medical, Inc.

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety determined by 30day New-Onset Serious Adverse Events	New Onset Serious Adverse Events (SAE) include death, device-related surgery or repeat hospitalization, occlusion, or major unplanned amputation through 30 days following the procedure.	30 day	Yes
Secondary	Angiographic Success as measured by residual stenosis <30% reference vessel.		Peri-Procedural	No